Yahoo
    OTC Markets OTCPK - Delayed Quote USD

    Kyowa Kirin Co., Ltd. (KYKOF)

    15.80 +0.40 (+2.60%)
    As of October 30 at 4:00:00 PM EDT. Market Open.
    Loading Chart for KYKOF
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Three-Year Real-World Study Compares Burosumab Treatment with Oral Phosphate and Active Vitamin D in Adults with XLH

    Three-Year Real-World Study Compares Burosumab Treatment with Oral Phosphate and Active Vitamin D in Adults with XLH
    GlobeNewswire 19d ago
    Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome

    Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome
    Business Wire 21d ago
    Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab

    Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
    Pharmaceutical Technology 1mo ago
    Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab

    Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
    Hospital Management 1mo ago
    Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America

    Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America
    Business Wire 1mo ago
    Knight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab)

    Knight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab)
    GlobeNewswire 1mo ago
    Is Kyowa Kirin (TSE:4151) A Bargain Following Its Share Price Pullback?

    Is Kyowa Kirin (TSE:4151) A Bargain Following Its Share Price Pullback?
    Simply Wall St. 1mo ago
    Tech, Oil Concerns Cramp Asian Stock Markets

    Tech, Oil Concerns Cramp Asian Stock Markets
    PREMIUM
    MT Newswires 1mo ago
    Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC

    Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC
    GlobeNewswire 1mo ago
    Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

    Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
    Benzinga 1mo ago
    Mid-cap biotechs join Trump’s latest round of drug pricing deals

    Mid-cap biotechs join Trump’s latest round of drug pricing deals
    BioPharma Dive 2mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: